Galderma Group AGXSWX:GALD -1.02%15 EBIT per Share is CHF2.76 as of Dec. 2025. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 4 warning signs investors should review. Among 810 Drug Manufacturers companies, Galderma Group AG ranks better than 72.22% on this metric.
Galderma Group AG's EBIT per Share for the
six
months ended in Dec. 2025 was CHF1.57.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF2.76.
During the past 12 months, the average EBIT per Share Growth Rate of Galderma Group AG was 15.90% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 22.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Galderma Group AG's EBIT per Share or its related term are showing as below:
XSWX:GALD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 22.4 Med: 22.6 Max: 22.8
Current: 22.8
During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Galderma Group AG was 22.80% per year. The lowest was 22.40% per year. And the median was 22.60% per year.
XSWX:GALD's 3-Year EBIT Growth Rate is ranked better than 72.22% of 810
companies
in the Drug Manufacturers industry
Industry Median: 7.65
vs XSWX:GALD: 22.80
Galderma Group AG (XSWX:GALD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Galderma Group AG EBIT per Share Related Terms
Galderma Group AG EBIT per Share Historical Data
* Premium members only.
The historical data trend for Galderma Group AG's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF2.76
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Galderma Group AG (XSWX:GALD) has a EBIT per Share of CHF2.76 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Galderma Group AG and its competitors. According to the industry distribution chart, Galderma Group AG ranks #225 out of 810 companies in the Drug Manufacturers industry, placing it in the top 27.8%.
Is Galderma Group AG's EBIT per Share too high?
Galderma Group AG's current EBIT per Share is CHF2.76. Based on the distribution chart, Galderma Group AG ranks #225 out of 810 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's EBIT per Share compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #225 out of 810 companies for EBIT per Share. This puts Galderma Group AG in the upper half of its industry. The industry median EBIT per Share is 7.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Drug Manufacturers company?
The median EBIT per Share among Drug Manufacturers companies is 7.65, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median EBIT per Share is 7.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current EBIT per Share is CHF2.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current EBIT per Share of CHF2.76. The current EBIT per Share is CHF2.76. Galderma Group AG's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current EBIT per Share is CHF2.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 